Mankind Pharma on Monday posted a 37.69% rise in profit to ₹716.12 crore in the September quarter, driven by strong business growth in domestic and international markets. The pharma company had posted a profit after tax (PAT) of ₹520.18 crore in the year-ago period, according to a regulatory filing. Revenue from operations increased to ₹4,337.86 crore during the quarter under review as against ₹3,697.16 crore in the year-ago period, the company said in a regulatory filing. “Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics marks strategic entry into Next-Generation CAR-T therapies, strengthening RD capabilities for future growth,” Vice Chairman Managing Director Rajeev Juneja said. The company posted strong domestic business growth of 15.9%, and 33% in the domestic market, he added. In the April-September period (H1) of FY27, the company posted a PAT of ₹1,290.21 crore, up from ₹964.8 crore, registering a growth of almost 33.7% the filing showed. Shares of the company on Monday settled 3.83% higher at ₹2,302 apiece on the BSE. Post navigation Applied in Reliance JIO IPO? Check if you got shares:Signs of 22% profit for investors; get step-by-step process here
